Want to join the conversation?
In Sept. 2015, $BIIB enrolled its first patient in its two global Phase 3 studies, ENGAGE & EMERGE, to assess the efficacy and safety of aducanumab in people with early Alzheimer's disease and triggered a $60MM milestone payment due to Neurimmune. $BIIB also received FDA agreement on a special protocol assessment on the aducanumab Phase 3 studies.
Still in yesterday’s $PZZA shock. I thought everyone had more pizza this football season!!
$TSLA stock downgraded to sell from hold by brokerage firm CFRA Research. However, the firm lifted the price target by $35 to $240.
$LB shares have plummeted after a disappointing quarter.